Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Venetoclax vs 7+3 in Younger FLT3WT ELN High-Risk AML
NCT04817241Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inqovi, venetoclax in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Feb 2022; status: active, not recruiting.
02
Drugs
inqovivenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04817241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817241.